Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $86.23, for a total value of $370,961.46. The sale was disclosed in a filing with the SEC, which is available at this link.

Palvella Therapeutics Trading Up 2.8%

Shares of NASDAQ:PVLA opened at $94.09 on Friday. The stock has a market cap of $1.11 billion, a PE ratio of -35.78 and a beta of -0.05. The stock’s fifty day simple moving average is $72.01 and its two-hundred day simple moving average is $47.10. Palvella Therapeutics, Inc. has a 1-year low of $11.17 and a 1-year high of $101.94.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, sell-side analysts forecast that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PVLA has been the topic of several recent analyst reports. Raymond James Financial raised shares of Palvella Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $92.00 to $143.00 in a research report on Wednesday. HC Wainwright increased their price target on Palvella Therapeutics from $95.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Canaccord Genuity Group boosted their price objective on Palvella Therapeutics from $90.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Oppenheimer restated an “outperform” rating on shares of Palvella Therapeutics in a research note on Tuesday, November 11th. Finally, Stifel Nicolaus lifted their target price on Palvella Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Palvella Therapeutics currently has an average rating of “Buy” and an average target price of $111.92.

Institutional Trading of Palvella Therapeutics

A number of large investors have recently bought and sold shares of the company. Clio Asset Management LLC purchased a new position in shares of Palvella Therapeutics during the 2nd quarter valued at $2,063,000. Woodline Partners LP bought a new stake in Palvella Therapeutics in the 1st quarter valued at about $5,435,000. Goldman Sachs Group Inc. purchased a new stake in Palvella Therapeutics during the first quarter valued at about $533,000. Frazier Life Sciences Management L.P. lifted its holdings in Palvella Therapeutics by 5.5% during the first quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock valued at $19,313,000 after purchasing an additional 36,120 shares during the last quarter. Finally, Royce & Associates LP bought a new position in Palvella Therapeutics during the first quarter worth about $2,002,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.